← All trials
NCT06844487
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Nov 30, 2026
- First posted
- Feb 25, 2025
- Last posted
- Aug 27, 2025
- Enrollment
- 344
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AntwerpLead sponsor
- PENTA FoundationCollaborator
- University of AntwerpSponsor investigator
- ace africaCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Bavarian NordicCollaborator
- University of KinshasaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.